Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Monopar Therapeutics Inc.

Market Cap 400M 346M 319M 298M 559M 38.06B 568M 3.76B 1.47B 18.52B 1.5B 1.47B 64.14B P/E Ratio 2026 *
-25.9x
P/E Ratio 2027 * -17.1x
Enterprise Value 282M 243M 224M 210M 393M 26.79B 400M 2.65B 1.03B 13.04B 1.06B 1.04B 45.15B EV / Sales 2026 *
-
EV / Sales 2027 * 18.7x
Free-Float
76.77%
Yield 2026 *
-
Yield 2027 * -
06-01 Monopar Therapeutics Presents Phase 2 Alxn1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients At Easl 2026 CI
05-19 Monopar Reports Publication of Phase 2 ALXN1840 Trial Data in Wilson Disease MT
05-19 Monopar Therapeutics Inc Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson Disease CI
05-14 Monopar Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
04-20 Monopar Therapeutics Inc. Presents Phase 3 Data Showing Greater Neurologic Benefit With ALXN1840 Versus Standard of Care In Wilson Disease Patients With Neurologic Symptoms CI
03-27 Monopar Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
03-02 Monopar expands leadership team with appointment of seasoned biopharma executive Susan Rodriguez as chief commercial and strategy officer RE
03-02 Monopar Therapeutics Inc. Appoints Susan Rodriguez as Chief Commercial and Strategy Officer, Effective from March 2, 2026 CI
01-09 Morgan Stanley Initiates Coverage on Monopar Therapeutics With Overweight Rating, $115 Price Target MT
12-19 Monopar Therapeutics Insider Sold Shares Worth $343,889, According to a Recent SEC Filing MT
11-14 Monopar Therapeutics Shares Fall After Raymond James Downgrade MT
11-14 Raymond James Downgrades Monopar Therapeutics to Outperform From Strong Buy, Adjusts PT to $123 From $142 MT
11-13 Monopar Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
1 day+1.14%
1 week+0.49%
Current month-8.10%
1 month-2.72%
3 months-0.98%
6 months-19.88%
Current year-8.47%
1 week 58.01
Extreme 58.01
62.23
1 month 54.21
Extreme 54.21
68.79
Current year 50.07
Extreme 50.07
76.13
1 year 29.18
Extreme 29.18
105
3 years 1.37
Extreme 1.3695
105
5 years 1.37
Extreme 1.3695
105
10 years 1.37
Extreme 1.3695
240
Manager TitleAgeSince
Chief Executive Officer 42 2014-11-30
Director of Finance/CFO 54 2025-03-02
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 63 2023-02-28
Chairman 73 2014-11-30
Director/Board Member 84 2017-03-31
Date Insider Type Main position Quantity % Market Cap.
03-30Fiscal year

Chief Operating Officer

8,599 0.1287%
03-30Fiscal year

Founder

15,436 0.2310%
03-01Free

Executive/Senior Manager

48,728 0.7292%
Change 5-day change 1-year change 3-year change Capi.($)
+1.14%+0.49%+78.31%+1,243.15% 400M
-0.35%+0.97%-13.80%-13.25% 43.03B
+3.11%+3.11%+279.08%+501.52% 32.71B
+0.22%-1.08%+15.66%-15.65% 30.29B
+1.62%-2.08%-1.91%+24.64% 29.4B
+4.09%+0.93%+12.97%+20.22% 25.08B
+1.14%+3.62% - - 13.54B
-1.63%+2.88%+56.69%+113.41% 13.35B
-0.40%-1.29%+6.23%+7.63% 12.97B
-0.74%-1.62%+105.89%+74.92% 12.11B
Average +0.82%+1.35%+59.90%+217.40% 21.29B
Weighted average by Cap. +1.05%+1.48%+57.34%+98.38%

Financials

2026 *2027 *
Net sales - 15.4M 13.31M 12.26M 11.48M 21.51M 1.46B 21.84M 145M 56.45M 713M 57.81M 56.58M 2.47B
Net income -20.16M -17.41M -16.05M -15.02M -28.15M -1.92B -28.58M -189M -73.87M -933M -75.66M -74.05M -3.23B -36.22M -31.28M -28.83M -26.98M -50.57M -3.44B -51.35M -340M -133M -1.68B -136M -133M -5.8B
Net Debt -119M -102M -94.37M -88.33M -166M -11.27B -168M -1.11B -434M -5.49B -445M -436M -18.99B -112M -97.03M -89.41M -83.69M -157M -10.68B -159M -1.06B -412M -5.2B -422M -413M -18B
Logo Monopar Therapeutics Inc.
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company developing treatments for Wilson disease and novel radiopharmaceuticals for oncology. The Company’s product candidates are ALXN1840, MNPR-101, MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac. The Company’s Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. Its radiopharmaceutical program consists of MNPR-101, a proprietary humanized monoclonal antibody that is being developed across multiple product candidates conjugated with different radioisotopes, for the treatment of advanced solid tumors. MNPR-101-Zr is the Company’s clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. MNPR-101-Lu is its clinical-stage radiotherapeutic comprised of MNPR-101 conjugated to lutetium-177. MNPR-101-Ac is late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.
Employees
22
Date Price Change Volume
26-06-12 59.77 $ +1.14% 154,406
26-06-11 59.10 $ -0.55% 79,073
26-06-10 59.42 $ -2.00% 81,012
26-06-09 60.63 $ +0.03% 167,459
26-06-08 60.61 $ +1.90% 78,242
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
59.77USD
Average target price
112.62USD
Spread / Average Target
+88.41%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MNPR Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!